Диссертация (1141381), страница 21
Текст из файла (страница 21)
– Т. 101. – №. 3. – С. 423-428.76. Clerc S., Barenholz Y. A quantitative model for using acridine orange as a transmembranepH gradient probe //Analytical biochemistry. – 1998. – Т. 259. – №. 1. – С. 104-111.77. Clerc S., Barenholz Y. Loading of amphipathic weak acids into liposomes in response totransmembrane calcium acetate gradients //Biochimica et Biophysica Acta (BBA)Biomembranes. – 1995.
– Т. 1240. – №. 2. – С. 257-265.78. ClinicalTrials.gov [homepage on the Internet]. Study of Liposome EncapsulatedMitoxantrone (LEM) in Patients With Advanced Cancer. Available from:http://clinicaltrials.gov/ct2/show/NCT00024492; [accessed 05.09.12].79. Cohen B. E., Bangham A.
D. Diffusion of small non-electrolytes across liposomemembranes. – 1972.80. Convention on the Elaboration of a European Pharmacopoeia. European Pharmacopoeia:Supplement. – Council of Europe, 1998.81. Corti, A. Tumor vascular targeting with Tumor Necrosis Factor–α and chemotherapeuticdrugs / A. Corti, M. Ponzoni // Ann. N.Y. Acad.
Sci. — 2004. — Vol. 1028. — P. 104–112.82. Crowe L. M. et al. Prevention of fusion and leakage in freeze-dried liposomes bycarbohydrates //Biochimica et Biophysica Acta (BBA)-Biomembranes. – 1986. – Т. 861. –С. 131-140.83. Cullis P. R., Hope M. J., Bally M. B.
Extrusion technique for producing unilamellarvesicles : пат. 5008050 США. – 1991.84. Cullis PR, Hope MJ, Bally MB, et al. Influence of pH gradients on the transbilayertransport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. BiochimBiophys Acta 1997;1331:187-21185. Cursiefen S., Flachenecker P., Rieckmann K.V. et al. Mitoxantron (Novantron) zurTherapie der schwerver laufen den multiplen Sklerose // Nervenarzt- 1999.-Vol.70.-P.723731.86. Cursiefen S., Flachenecker PP., Toyka K. et al. Escalating immunotherapy withmitoxantrone in patients with very active relapsing remitting or progressive multiplesclerosis // European neurology.- 2000.-Vol. 43, N 3.-P.186-187.87.
D.D. Lasic, B. Ceh, M.C. Stuart, L. Guo, P.M. Frederik, Y. Barenholz, Transmembranegradient driven phase transitions within vesicles: lessons for drug delivery, Biochim.Biophys. Acta 1239 (2) (1995) 145–1588. Danielli JF, Davson H (1925) A contribution to the theory of permebaility of thin films. JCell Comp Physiol 5:495–50889. Dasa S., Bhattacharyaa A., Mandala P.C, One-electron reduction of 1,2-dihydroxy-9,10anthraquinone and some of its transition metal complexes in aqueous solution and inaqueous isopropanol-acetone-mixed solvent: a steady-state and pulse radiolysis study//Radiation Physics and Chemistry.- 2002.- Vol.
65.-P. 93-100.90. De Isabella PP., Capranico G., Palumbo M. Sequence selectivity of topoisomerase II DNAcleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding andcellular effects // Molecular Pharmacology. –Vol.43, N 5.-1993.- P. 715-721.91.
Deamer D, Bangham AD: Large volume liposomes by an ether vaporization method.Biochim Biophys Acta 1976, 443(3):629–634.92. Dragovich T. et al. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patientswith therapy-refractory advanced colorectal cancer //Cancer chemotherapy andpharmacology. – 2006. – Т. 58.
– №. 6. – С. 759-764.93. Drakaki A., Hurvitz S. A. HER2-Positive Breast Cancer: Update on New and EmergingAgents //American Journal of Hematology/Oncology®. – 2015. – Т. 11. – №. 4.12694. Dromi S. et al. Pulsed-high intensity focused ultrasound and low temperature–sensitiveliposomes for enhanced targeted drug delivery and antitumor effect //Clinical CancerResearch. – 2007. – Т. 13. – №. 9. – С. 2722-2727.95.
Drummond D. C. et al. Optimizing liposomes for delivery of chemotherapeutic agents tosolid tumors //Pharmacological reviews. – 1999. – Т. 51. – №. 4. – С. 691-744.96. Duffaud F. et al. Phase II study of OSI-211 (liposomal lurtotecan) in patients withmetastatic or loco-regional recurrent squamous cell carcinoma of the head and neck: anEORTC New Drug Development Group study //European Journal of Cancer.
– 2004. – Т.40. – №. 18. – С. 2748-2752.97. Edwards K.A., Baeummer A.J. Analysis of liposomes // Talanta. – 2006. – № 68. – С.1432-1441.98. Ehninger G, Schuler U, Proksch B. et al. Pharmacokinetics and metabolism ofmitoxantrone // Clinical Pharmacokinetics.-1990.-Т.18. – № 5. – С.365-380.99. Enoch H.
G., Strittmatter P. Formation and properties of 1000-A-diameter, single-bilayerphospholipid vesicles //Proceedings of the National Academy of Sciences. – 1979. – Т. 76.– №. 1. – С. 145-149.100. Fantini M. et al. Lipoplatin treatment in lung and breast cancer //Chemotherapy researchand practice. – 2010. – Т.
2011.101. Fasol U. et al. Vascular and pharmacokinetic effects of EndoTAG-1 in patients withadvanced cancer and liver metastasis //Annals of oncology. – 2011. – С. mdr300.102. Fassas A., Anagnostopoulos A. The use of liposomal daunorubicin (DaunoXome) inacute myeloid leukemia //Leukemia & lymphoma. – 2005.
– Т. 46. – №. 6. – С. 795-802.103. Faulds D. et al. Mitoxantrone //Drugs. – 1991. – Т. 41. – №. 3. – С. 400-449.104. Feldman E. J. et al. First-in-man study of CPX-351: a liposomal carrier containingcytarabine and daunorubicin in a fixed 5: 1 molar ratio for the treatment of relapsed andrefractory acute myeloid leukemia //Journal of Clinical Oncology. – 2011. – Т. 29. – №. 8.– С. 979-985.105.
Fetterly G. J. et al. Pharmacokinetic/pharmacodynamic modeling and simulation ofneutropenia during phase I development of liposome-entrapped paclitaxel //Clinical CancerResearch. – 2008. – Т. 14. – №. 18. – С. 5856-5863.106. Florey K. et al. Analytical profiles of drug substances and excipients. – Academic press,1992. – Т. 20.107. Floyd J. et al. Cardiotoxicity of anthracycline-like chemotherapy agents //UpToDate,Waltham, MA. – 2014. – Т. 2014.108. Fox E.
J. Mechanism of action of mitoxantrone //Neurology. – 2004. – Т. 63. – №. 12suppl 6. – С. S15-S18.109. G. Gregoriadis, “Liposome research in drug delivery: the early days,” Journal of DrugTargeting, vol. 16, no. 7-8, pp. 520–524, 2008.110. Gabizon A., Papahadjopoulos D. Liposome formulations with prolonged circulationtime in blood and enhanced uptake by tumors //Proceedings of the National Academy ofSciences. – 1988. – Т. 85. – №.
18. – С. 6949-6953.111. Garbuzenko O. et al. Electrostatics of PEGylated micelles and liposomes containingcharged and neutral lipopolymers //Langmuir. – 2005. – Т. 21. – №. 6. – С. 2560-2568.112. Garbuzenko O., Barenholz Y., Priev A. Effect of grafted PEG on liposome size and oncompressibility and packing of lipid bilayer //Chemistry and physics of lipids. – 2005. – Т.135. – №. 2.
– С. 117-129.113. Gardikis K. et al. New chimeric advanced Drug Delivery nano Systems (chi-aDDnSs)as doxorubicin carriers //International journal of pharmaceutics. – 2010. – Т. 402. – №. 1. –С. 231-237.114. Geciova J., Bury D., Jelen P. Methods for disruption of microbial cells for potential usein the dairy industry—a review //International Dairy Journal. – 2002. – Т. 12. – №.
6. – С.541-553.127115. GERRITSEN W. J. et al. Freeze‐Fracture Appearance and Disposition of Band 3Protein from the Human Erythrocyte Membrane in Lipid Vesicles //European Journal ofBiochemistry. – 1978. – Т. 85. – №. 1. – С. 255-261.116. Gill P. S. et al. Randomized phase III trial of liposomal daunorubicin versusdoxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma //Journal ofClinical Oncology. – 1996. – Т.
14. – №. 8. – С. 2353-2364.117. Gorter E., Grendel F. On bimolecular layers of lipoids on the chromocytes of the blood//The Journal of experimental medicine. – 1925. – Т. 41. – №. 4. – С. 439-443.118. Goyal P. et al. Liposomal drug delivery systems-clinical applications //Actapharmaceutica. – 2005. – Т. 55. – №. 1. – С. 1-25.119. Gregoriadis G. The carrier potential of liposomes in biology and medicine //NewEngland Journal of Medicine. – 1976. – Т. 295. – №. 13. – С. 704-710.120. Gregoriadis G., Leathwood P.
D., Ryman B. E. Enzyme entrapment in liposomes//FEBS letters. – 1971. – Т. 14. – №. 2. – С. 95-99.121. Gregoriadis G., Ryman B. E. Liposomes as carriers of enzymes or drugs: a newapproach to the treatment of storage diseases //Biochemical Journal. – 1971. – Т. 124. – №.5. – С.
58P.122. Hansen C. B. et al. Attachment of antibodies to sterically stabilized liposomes:evaluation, comparison and optimization of coupling procedures //Biochimica etBiophysica Acta (BBA)-Biomembranes. – 1995. – Т. 1239. – №. 2. – С. 133-144.123. Haran G. et al. Transmembrane ammonium sulfate gradients in liposomes produceefficient and stable entrapment of amphipathic weak bases //Biochimica et Biophysica Acta(BBA)-Biomembranes. – 1993. – Т. 1151.
– №. 2. – С. 201-215.124. Harrington K. J. et al. Phase I-II study of pegylated liposomal cisplatin (SPI-077 TM) inpatients with inoperable head and neck cancer //Annals of oncology. – 2001. – Т. 12. – №.4. – С. 493-496.125. Hartrick C. T., Hartrick K. A. Extended-release epidural morphine (DepoDur™):review and safety analysis //Expert review of neurotherapeutics.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
